Co-Authors
This is a "connection" page, showing publications co-authored by Matthew Snape and Paul Klenerman.
Connection Strength
0.220
-
First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults. Clin Infect Dis. 2020 05 06; 70(10):2073-2081.
Score: 0.220